Company profile
ImmunityBio, Inc.
NASDAQ: IBRX · Healthcare · Biotechnology
#336 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
58CFH 37DQ 79GM 68SS 76
v0.1 · 65/100 weight · provisional
↑ 3-yr revenue growth, revenue growth (YoY) · ↓ growth stability, balance-sheet leverage
Methodology →Revenue TTM
$113.3M
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$351.4M
Employees
691
as of 2026-08-06
Market cap
$7.6B
as of 2026-08-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$113.3M$113.3M2025
Net income-$351.4M-$351.4M2025
Operating income-$256.0M-$256.0M2025
Total assets$501.9M$501.9M2025
Liabilities$1.0B$1.0B2025
Equity-$500.5M-$500.5M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY21
FY21
FY24
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product100%
Product and Service, Other0%
By geography
Not disclosed.
The read
What is ImmunityBio, Inc.’s revenue?
ImmunityBio, Inc. booked $113.3M in FY2025 revenue, growing 668% year over year — faster than 95% of Healthcare companies we track, at a -310.2% net margin.
Peers · Healthcare
Gyre Therapeutics, Inc.72BOraSure Technologies, Inc.67BAgenus Inc.67BAnika Therapeutics, Inc.74BUroGen Pharma Ltd.55COptimizeRx Corp.72BNeighbors
San Diego →Key facts
CEORichard Gerald Adcock
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: IBRX
Employees691
IPO date2015-07-28
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.